Lv7
4680 积分 2022-05-26 加入
Novel Treatment Options for Multiple Myeloma
20小时前
待确认
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
2个月前
已完结
multiple myeloma
6个月前
已完结
Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T Cell Therapy in Multiple Myeloma
7个月前
已关闭
Daratumumab and Venetoclax-Containing Regimens in the Management of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Hematological Malignancies
7个月前
已关闭
Immunotherapy in Multiple Myeloma: Experience of the Multiple Myeloma Gimema Lazio Group
7个月前
已完结
Feasibility and Benefit of Molecularly-Informed Enrollment into Personalized Therapies or Early Phase Trials for Patients with Relapsed or Refractory Multiple Myeloma
7个月前
已完结
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
8个月前
已完结
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial
8个月前
已完结
Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future
8个月前
已完结
皖公网安备34019202002308
